OncoAssure Ltd, an Irish medical diagnostic company, announced the publication of new data in the journal BJUI Compass that demonstrate the clinical validation of OncoAssure Prostate, a novel biopsy test that provides improved ...
Jan 21, 2025
0
0
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical ...
Jan 10, 2025
0
1
Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player ...
Jan 8, 2025
0
6
Regular physical activity before a cancer diagnosis may lower the risks of both disease progression and death, suggests research published online in the British Journal of Sports Medicine.
Jan 7, 2025
0
1
Steam eliminates wrinkles and germs, but can it destroy cancer cells too?
Jan 7, 2025
0
4
A study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.
Jan 3, 2025
0
41
In April 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient's electronic medical record as soon as they become available. As a result of this ...
Jan 3, 2025
0
15
Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called metastatic or stage 4 prostate cancer. While most advanced prostate cancer is incurable, treatments can ...
Dec 23, 2024
0
1
There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next step typically involves ...
Dec 19, 2024
0
2
A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer.
Dec 19, 2024
0
22
